It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APTO’s FA Score shows that 0 FA rating(s) are green whileLCTX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APTO’s TA Score shows that 6 TA indicator(s) are bullish while LCTX’s TA Score has 5 bullish TA indicator(s).
APTO (@Biotechnology) experienced а -2.77% price change this week, while LCTX (@Biotechnology) price change was -18.14% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.12%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was -1.61%.
APTO is expected to report earnings on Aug 10, 2023.
LCTX is expected to report earnings on Mar 06, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
APTO | LCTX | APTO / LCTX | |
Capitalization | 11M | 111M | 10% |
EBITDA | N/A | N/A | - |
Gain YTD | -92.961 | -53.991 | 172% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | 2.9M | N/A | - |
Total Debt | 919K | 3.25M | 28% |
APTO | LCTX | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 97 | |
PRICE GROWTH RATING 1..100 | 97 | 95 | |
P/E GROWTH RATING 1..100 | 100 | 66 | |
SEASONALITY SCORE 1..100 | n/a | 95 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
LCTX's Valuation (38) in the null industry is somewhat better than the same rating for APTO (90) in the Biotechnology industry. This means that LCTX’s stock grew somewhat faster than APTO’s over the last 12 months.
LCTX's Profit vs Risk Rating (100) in the null industry is in the same range as APTO (100) in the Biotechnology industry. This means that LCTX’s stock grew similarly to APTO’s over the last 12 months.
LCTX's SMR Rating (97) in the null industry is in the same range as APTO (100) in the Biotechnology industry. This means that LCTX’s stock grew similarly to APTO’s over the last 12 months.
LCTX's Price Growth Rating (95) in the null industry is in the same range as APTO (97) in the Biotechnology industry. This means that LCTX’s stock grew similarly to APTO’s over the last 12 months.
LCTX's P/E Growth Rating (66) in the null industry is somewhat better than the same rating for APTO (100) in the Biotechnology industry. This means that LCTX’s stock grew somewhat faster than APTO’s over the last 12 months.
APTO | LCTX | |
---|---|---|
RSI ODDS (%) | 1 day ago75% | 1 day ago79% |
Stochastic ODDS (%) | 1 day ago73% | 1 day ago90% |
Momentum ODDS (%) | 1 day ago90% | 1 day ago83% |
MACD ODDS (%) | 1 day ago80% | 1 day ago84% |
TrendWeek ODDS (%) | 1 day ago90% | 1 day ago83% |
TrendMonth ODDS (%) | 1 day ago90% | 1 day ago83% |
Advances ODDS (%) | 7 days ago79% | 9 days ago80% |
Declines ODDS (%) | 1 day ago90% | 3 days ago82% |
BollingerBands ODDS (%) | 1 day ago70% | 1 day ago80% |
Aroon ODDS (%) | 1 day ago85% | 1 day ago87% |
A.I.dvisor tells us that APTO and LCTX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APTO and LCTX's prices will move in lockstep.
Ticker / NAME | Correlation To APTO | 1D Price Change % | ||
---|---|---|---|---|
APTO | 100% | -4.69% | ||
LCTX - APTO | 31% Poorly correlated | +0.93% | ||
ORMP - APTO | 25% Poorly correlated | +2.13% | ||
ORIC - APTO | 24% Poorly correlated | -6.91% | ||
INBX - APTO | 23% Poorly correlated | -3.16% | ||
BNOX - APTO | 23% Poorly correlated | -4.03% | ||
More |
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with GBIO. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then GBIO could also see price increases.
Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
---|---|---|---|---|
LCTX | 100% | +0.93% | ||
GBIO - LCTX | 33% Loosely correlated | -6.42% | ||
MGTX - LCTX | 32% Poorly correlated | -8.75% | ||
ABSI - LCTX | 31% Poorly correlated | -8.71% | ||
APTO - LCTX | 31% Poorly correlated | -4.69% | ||
NTLA - LCTX | 30% Poorly correlated | -8.45% | ||
More |